Efficacy and Pharmacokinetics of a Modified acid-labile docetaxel-PRINT <sup>®</sup> Nanoparticle Formulation Against non-small-cell Lung Cancer Brain Metastases
Maria J. Sambade(University of North Carolina at Chapel Hill), Carey K. Anders(Duke University), J. Christopher Luft(UNC Lineberger Comprehensive Cancer Center), Allison N. Schorzman(University of North Carolina at Chapel Hill), Allison M. Deal(Memorial Sloan Kettering Cancer Center), Olga Karginova(University of Illinois Chicago), William C. Zamboni(AstraZeneca (United Kingdom)), Joseph M. DeSimone(Cancer Prevention Institute of California), Amanda E.D. Van Swearingen(Duke Cancer Institute), Kevin S. Chu(University of North Carolina at Chapel Hill), Charles J. Bowerman(University of North Carolina at Chapel Hill)
Cited by 30
Related Papers
Symptom Monitoring With Patient-Reported Outcomes During Routine Cancer Treatment: A Randomized Controlled Trial
|Journal of Clinical Oncology|2015|2.6k
Overall Survival Results of a Trial Assessing Patient-Reported Outcomes for Symptom Monitoring During Routine Cancer Treatment
|JAMA|2017|2.3k
Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer
|Breast Cancer Research|2010|2.1k
Challenges and Key Considerations of the Enhanced Permeability and Retention Effect for Nanomedicine Drug Delivery in Oncology
|Cancer Research|2013|1.5k
Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer
|New England Journal of Medicine|2019|1.3k